Literature DB >> 26710309

Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States--A Single-Center Experience.

G Y Im1, L Kim-Schluger1, A Shenoy2, E Schubert3, A Goel4, S L Friedman4, S Florman1, T D Schiano1.   

Abstract

Early liver transplantation (LT) in European centers reportedly improved survival in patients with severe alcoholic hepatitis (AH) not responding to medical therapy. Our aim was to determine if a strategy of early LT for severe AH could be applied successfully in the United States. We reviewed 111 patients with severe AH at our center from January 2012 to January 2015. The primary end point was mortality at 6 months or early LT, with a secondary end point of alcohol relapse after LT. Survival was compared between those receiving early LT and matched patients who did not. Using a process similar to the European trial, 94 patients with severe AH not responding to medical therapy were evaluated for early LT. Overall, 9 (9.6%) candidates with favorable psychosocial profiles underwent early LT, comprising 3% of all adult LT during the study period. The 6-month survival rate was higher among those receiving early LT compared with matched controls (89% vs 11%, p<0.001). Eight recipients are alive at a median of 735 days with 1 alcohol relapse. Early LT for severe AH can achieve excellent clinical outcomes with low impact on the donor pool and low rates of alcohol relapse in highly selected patients in the United States. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Focus: alcoholism and substance abuse; Scope: clinical research/practice; health services and outcomes research Discipline: liver transplantation/hepatology; liver disease

Mesh:

Year:  2015        PMID: 26710309     DOI: 10.1111/ajt.13586

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  44 in total

1.  Current Management of Alcohol-Associated Liver Disease.

Authors:  Faisal A Siddiqi; Krishna C Sajja; Nyan L Latt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-11

Review 2.  Alcoholic hepatitis: Towards an era of personalised management.

Authors:  Delphine Degré; Line C Ntandja Wandji; Christophe Moreno; Alexandre Louvet
Journal:  United European Gastroenterol J       Date:  2020-07-27       Impact factor: 4.623

Review 3.  Con: The Abstinence Period Should Be Determined on a Case-by-Case Basis.

Authors:  Nikhilesh Mazumder; Justin Boike; Haripriya Maddur
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-03-29

Review 4.  Alcohol-Associated Liver Disease: East Versus West.

Authors:  Phunchai Charatcharoenwitthaya; Suthat Liangpunsakul; Teerha Piratvisuth
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-01-13

5.  Controversies in Liver Transplantation.

Authors:  James F Trotter
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-02

6.  Medicaid Policy and Liver Transplant for Alcohol-Associated Liver Disease.

Authors:  Brian P Lee; Eric Vittinghoff; Mark J Pletcher; Jennifer L Dodge; Norah A Terrault
Journal:  Hepatology       Date:  2020-05-08       Impact factor: 17.425

7.  Early Liver Transplantation is a Viable Treatment Option in Severe Acute Alcoholic Hepatitis.

Authors:  Puneet Puri; George Cholankeril; Thomas Y Myint; Aparna Goel; Shiv Kumar Sarin; Ann M Harper; Aijaz Ahmed
Journal:  Alcohol Alcohol       Date:  2018-11-01       Impact factor: 2.826

Review 8.  Early Liver Transplantation for Severe Alcoholic Hepatitis.

Authors:  Jessica L Mellinger; Jonathan G Stine
Journal:  Dig Dis Sci       Date:  2020-06       Impact factor: 3.199

Review 9.  Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease.

Authors:  Lorenzo Leggio; Mary R Lee
Journal:  Am J Med       Date:  2016-10-29       Impact factor: 4.965

Review 10.  Grand Rounds: Alcoholic Hepatitis.

Authors:  Ashwani K Singal; Alexandre Louvet; Vijay H Shah; Patrick S Kamath
Journal:  J Hepatol       Date:  2018-06-13       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.